Search

Ireland: Cost-Efficient Bio-Manufacturing GE Invests in Biopharmaceutical Campus

| Editor: Alexander Stark

Ireland’s Minister for Jobs, Enterprise and Innovation, Mary Mitchell O’Connor TD, announced that GE is to invest € 150 million in a new biopharmaceutical manufacturing campus on Industrial Development Agency (IDA) Ireland’s strategic site at Loughbeg, Ringaskiddy, Cork.

Related Companies

GE BioPark Cork will include four fully-equiped KUBio factories owned by independent biopharma companies manufacturing proprietary medicines, GE running centralized shared utilities and site services.
GE BioPark Cork will include four fully-equiped KUBio factories owned by independent biopharma companies manufacturing proprietary medicines, GE running centralized shared utilities and site services.
(Source: GE)

Cork/Ireland — GE BioPark Cork, subject to contract and planning approvals, will feature Europe’s first Kubio, prefabricated, off-the-shelf bio-manufacturing facilities, owned and run by GE customers, and will serve as focal point for further investment in next-generation biopharmaceutical manufacturing in Ireland. The construction phase, subject to planning approvals, is expected to begin by mid- 2017 and create up to 800 construction jobs. The project is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.

GE and the National Institute for Bioprocessing Research and Training (NIBRT) also announced their plan to create a Single-use Centre of Excellence at NIBRT’s Dublin facility. The company expects to train up to 1,500 bioprocessing professionals annually on next-generation biologic manufacturing technologies. These exceptional technologies for biopharma manufacturing will be used in GE BioPark Cork’s manufacturing facilities.

GE BioPark Cork will be a GE-managed campus including four fully-equipped KUBio factories owned by independent biopharma companies manufacturing proprietary medicines, with GE running centralised shared utilities and site services.

(ID:44284707)